ConductScience.org, home

Paper41258724

Unlocking potentials: the impact of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam in combating carbapenem-resistant Enterobacter cloacae.

Lavoie T and 5 others. Antimicrob Agents Chemother, 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Unlocking potentials: the impact of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam in combating carbapenem-resistant Enterobacter cloacae. Papers, record 41258724. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41258724

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Unlocking potentials: the impact of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam in combating carbapenem-resistant Enterobacter cloacae.
PubMed
Journal
Antimicrob Agents Chemother
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-05-13
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Lavoie TThomashttps://orcid.org/0009-0005-4842-3381
2Sierra TTeresa
3Daffinee KKatiehttps://orcid.org/0000-0002-1942-3033
4Pogue JMJason Mhttps://orcid.org/0000-0003-4780-6215
5Achour BBrahim
6LaPlante KKerryhttps://orcid.org/0000-0002-9650-4275

Source PubMed

Download CSV of authors

Topics15

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CeftazidimeMajor topic
MeropenemMajor topic
Enterobacter cloacaeMajor topic
Azabicyclo CompoundsMajor topic
Anti-Bacterial AgentsMajor topic
Carbapenem-Resistant EnterobacteriaceaeMajor topic
Boronic AcidsMajor topic
Drug Combinations
Microbial Sensitivity Tests
Humans
beta-Lactamases
Bacterial Proteins
Carbapenems
Enterobacteriaceae Infections
Heterocyclic Compounds, 1-Ring

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
Melinta TherapeuticsPubMed

Source PubMed

Download CSV of grants

References49

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128039276The pharmacodynamics of avibactam in combination with ceftaroline or ceftazidime against β-lactamase-producing Enterobacteriaceae studied in an in vitro model of infection.J Antimicrob Chemother2017https://conductscience.org/library/papers/28039276PubMed
226926624Ampicillin in Combination with Ceftaroline, Cefepime, or Ceftriaxone Demonstrates Equivalent Activities in a High-Inoculum Enterococcus faecalis Infection Model.Antimicrob Agents Chemother2016https://conductscience.org/library/papers/26926624PubMed
315561842Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.Antimicrob Agents Chemother2004https://conductscience.org/library/papers/15561842PubMed
430020449Ceftazidime/Avibactam, Meropenem/Vaborbactam, or Both? Clinical and Formulary Considerations.Clin Infect Dis2019https://conductscience.org/library/papers/30020449PubMed
534430671Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa.Open Forum Infect Dis2021https://conductscience.org/library/papers/34430671PubMed
633318006Minocycline Alone and in Combination with Polymyxin B, Meropenem, and Sulbactam against Carbapenem-Susceptible and -Resistant Acinetobacter baumannii in an In Vitro Pharmacodynamic Model.Antimicrob Agents Chemother2021https://conductscience.org/library/papers/33318006PubMed
732151332Molecular and clinical epidemiology of carbapenem-resistant Enterobacterales in the USA (CRACKLE-2): a prospective cohort study.Lancet Infect Dis2020https://conductscience.org/library/papers/32151332PubMed
835976531
Ceftazidime/Avibactam-Based Versus Polymyxin B-Based Therapeutic Regimens for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infection in Critically Ill Patients: A Retrospective Cohort Study.
Infect Dis Ther2022https://conductscience.org/library/papers/35976531PubMed
930219824Renal Dosing of Antibiotics: Are We Jumping the Gun?Clin Infect Dis2019https://conductscience.org/library/papers/30219824PubMed
1030270406Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial.Infect Dis Ther2018https://conductscience.org/library/papers/30270406PubMed
1124867993
Activity of daptomycin or linezolid in combination with rifampin or gentamicin against biofilm-forming Enterococcus faecalis or E. faecium in an in vitro pharmacodynamic model using simulated endocardial vegetations and an in vivo survival assay using Galleria mellonella larvae.
Antimicrob Agents Chemother2014https://conductscience.org/library/papers/24867993PubMed
1226125030Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections.Open Forum Infect Dis2015https://conductscience.org/library/papers/26125030PubMed
1316251324Kinetics study of KPC-3, a plasmid-encoded class A carbapenem-hydrolyzing beta-lactamase.Antimicrob Agents Chemother2005https://conductscience.org/library/papers/16251324PubMed
1432755654Clinical and Microbiological Analysis of Risk Factors for Mortality in Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia.Int J Antimicrob Agents2020https://conductscience.org/library/papers/32755654PubMed
1536374023Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints.Antimicrob Agents Chemother2022https://conductscience.org/library/papers/36374023PubMed
1629133570Activity of Simulated Human Dosage Regimens of Meropenem and Vaborbactam against Carbapenem-Resistant Enterobacteriaceae in an In Vitro Hollow-Fiber Model.Antimicrob Agents Chemother2018https://conductscience.org/library/papers/29133570PubMed
1724970941Time to Administration of Antibiotics among Inpatients with Severe Sepsis or Septic Shock.Can J Hosp Pharm2014https://conductscience.org/library/papers/24970941PubMed
1836968951Impact of ompk36 genotype and KPC subtype on the in vitro activity of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam against KPC-producing K. pneumoniae clinical isolates.JAC Antimicrob Resist2023https://conductscience.org/library/papers/36968951PubMed
1932015049Considerations in the Selection of Renal Dosage Adjustments for Patients with Serious Infections and Lessons Learned from the Development of Ceftazidime-Avibactam.Antimicrob Agents Chemother2020https://conductscience.org/library/papers/32015049PubMed
2029507064Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections.Antimicrob Agents Chemother2018https://conductscience.org/library/papers/29507064PubMed

See all 49 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41258724

GET https://conductscience.org/api/papers/v1/41258724/references?page=2